Evidence map›Paper›PMID 42415217›Full record

ArticleMicrobiologyOpen2026

Effects of the HDAC6/8 Inhibitor MC1568, Alone and in Combination With Fluconazole, in Non-Albicans Candida Species Infections.

Andrea Giammarino, Chiara Lambona, Alessia Raucci, Giovanna Simonetti, Salvatore Macrì, Angela Iuzzolino, Daniela Trisciuoglio, Sergio Valente, Gustavo Giusiano, Letizia Angiolella and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrea GiammarinoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Chiara LambonaDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy.
Alessia RaucciDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy.
Giovanna SimonettiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Salvatore MacrìDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy.
Angela IuzzolinoIBPM Institute of Molecular Biology and Pathology, CNR National Research Council of Italy, Rome, Italy.
Daniela TrisciuoglioIBPM Institute of Molecular Biology and Pathology, CNR National Research Council of Italy, Rome, Italy.
Sergio ValenteDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy.
Gustavo GiusianoDepartamento de Micología, Instituto de Medicina Regional, Universidad Nacional del Nordeste, Argentina.
Letizia AngiolellaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-0473-5587
Antonello MaiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy.

Funding

This study was supported by Ricerca Ateneo Sapienza Project protocs. RP12218147BEEF07 (2022, to L.A.), RM123188F708EDE9 (2023, to S.V.), AR12419078302CFC (2024, to A.R.), and AR12419074CF44D8 (2024, to C.L.), and PRIN2020 CW39SJ (to S. V.).
6 · The paper itself

Abstract

Fungal infections pose a severe health risk, particularly in immunocompromised individuals, with Candida species being a leading cause of bloodstream infections. The rise of non-albicans Candida (NAC) infections, accounting for 35%-65% of candidemia cases, underscores the urgent need for novel antifungal strategies. Current treatments, including echinocandins and azoles, are increasingly challenged by drug-resistant strains. This study evaluated the antifungal efficacy of three clinically approved histone deacetylase inhibitors (HDACi)-Vorinostat, Romidepsin, and Tucidinostat-along with the HDAC6/8-selective inhibitor MC1568, alone and in combination with Fluconazole. The Fluconazole/MC1568 combination exhibited significant synergistic effects, reducing biofilm formation and enhancing antifungal activity, particularly against C. guillermondii, C. lusitaniae, and C. tropicalis. In Galleria mellonella larvae, this combination increased survival by 70% in C. tropicalis infections. When tested in human retinal pigment epithelium (RPE) cells, three different MC1568/Fluconazole combinations displayed low toxicity. These findings highlight the potential of the HDAC6/8 inhibitor MC1568 as adjunct therapy to combat NAC infections, warranting further research to optimize antifungal efficacy while minimizing toxicity.

Indexed as

Antifungal AgentsCandidaCandidiasisFluconazoleHistone Deacetylase InhibitorsAnimalsBiofilmsDrug SynergismHistone Deacetylase 6HumansHydroxamic AcidsLarvaMicrobial Sensitivity TestsPyrimidinesAntifungal AgentsFluconazoleHistone Deacetylase 6Histone Deacetylase InhibitorsHydroxamic AcidsPyrimidinesricolinostatadherencebiofilmCandida sppdrug combinationGalleria mellonella modelhistone deacetylaseslysine deacetylation

Identifiers

PMID42415217
PMCPMC13341649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.